Full Press Release Details
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare
Capital Partners, New Enterprise Associates (NEA), and Nextech
Pro forma cash and investments expected to fund current operating
SOUTH SAN FRANCISCO and SAN DIEGO, CA January 22, 2024 ORIC Pharmaceuticals, Inc.
(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it has agreed to sell approximately 12.5 million shares of its common stock to a select
group of institutional and accredited healthcare specialist investors in a private placement, at a price per share of $10.00, representing a premium of approximately 10% to ORIC s 5-day trailing average
price. The financing is expected to close on January 23, 2024, subject to customary closing conditions. ORIC anticipates the gross proceeds from the private placement to be approximately $125 million, before deducting any offering related
The financing includes participation from new and existing institutional investors, including Viking Global Investors, Commodore Capital,
Frazier Life Sciences, Venrock Healthcare Capital Partners, NEA, and Nextech1.
the net proceeds from the proposed financing to fund research and development of its clinical-stage product candidates and research programs and for working capital and general corporate purposes. The proceeds from this financing, combined with
current cash, cash equivalents and marketable securities, is expected to be sufficient to fund the current operating plan into late 2026.
described above have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption
from the registration
requirements of the Securities Act. ORIC has agreed to file a registration statement with the U.S. Securities and Exchange
Commission (the SEC ) registering the resale of the shares of common stock issued in this private placement. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients lives by Overcoming Resistance In Cancer.
ORIC s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being
developed across multiple genetically defined cancers, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment
regimens, being developed for multiple myeloma. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego,
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the
timing and expectation of the closing of the private placement; the satisfaction of customary closing conditions related to the private placement and the anticipated use of proceeds therefrom; and the period over which ORIC estimates the proceeds
from the private placement, combined with its existing cash, cash equivalents and marketable securities, will be sufficient to fund its current operating plan. Words such as believes, anticipates, plans,
expects, intends, will, goal, potential and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon
ORIC s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties,
including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC s ability to
develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC s plans to develop and commercialize its product candidates; the potential for
clinical trials of ORIC-533, ORIC-114, ORIC-944 or any other product candidates to differ from preclinical, initial, interim,
preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that
could give rise to the termination of ORIC s license and collaboration agreements; regulatory developments in the United States and foreign countries; ORIC s reliance on third parties, including contract manufacturers and contract research
organizations; ORIC s ability to obtain and maintain
intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market
conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled Risk Factors in ORIC s Quarterly Report on Form 10-Q filed with the
SEC on November 6, 2023, and ORIC s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to
update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Dominic Piscitelli, Chief Financial Officer